Natalizumab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 3572 publications
The wearing-off effect with natalizumab: Back to the drawing board.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: March 27, 2026
Cytomegalovirus Drives the Development of Cytotoxic CD4+ T Cells in Patients With Multiple Sclerosis.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: March 23, 2026
Threshold-Dependent Discordance Between STRATIFY JCV™ and IMMUNOWELL™ Assays in Relapsing Multiple Sclerosis.
Journal: Neurology and therapy
Published: February 23, 2026
Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments: A Multicenter Cohort Study.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: February 20, 2026
Natalizumab exacerbates astrocytopathy in NMOSD via blockade of endothelial VCAM1-astrocytic integrin α4 interaction.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: February 11, 2026
Hematopoietic stem cell transplantation for multiple sclerosis: Improving understanding and addressing misconceptions.
Journal: Handbook of clinical neurology
Published: January 12, 2026
Cladribine for people with multiple sclerosis.
Journal: The Cochrane database of systematic reviews
Published: January 09, 2026
Corrigendum to "Physiologically-based pharmacokinetic modeling of natalizumab for multiple sclerosis patients to predict the withdrawal time in pregnancy and vaccine time in infants" [European Journal of Pharmaceutical Sciences, 215 (2025), 107301].
Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
Published: January 08, 2026
Cost-effectiveness of treatment sequences following first-line rituximab in relapsing-remitting multiple sclerosis: a Norwegian microsimulation study.
Journal: Frontiers in neurology
Published: January 08, 2026
NX210c Demonstrates Therapeutic Potential to Restore Blood-Brain Barrier in a QSP Model of Relapsing-Remitting Multiple Sclerosis.
Journal: International journal of molecular sciences
Published: December 23, 2025
Managing reactivation of multiple sclerosis during treatment with natalizumab.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: December 20, 2025
Author response to letter to the editor.
Journal: Journal of the neurological sciences
Published: December 19, 2025
Last Updated: 04/28/2026